The honest answer to how long a compounded preparation keeps is that only the dispensing pharmacy can say, because the beyond-use date it assigned to that batch is the whole answer. No general figure exists. What follow-up can do is make sure somebody is actually tracking that date, that the lot is documented, and that refills arrive before it lapses.

Two different dating systems, two different owners

An approved medicine carries an expiration date generated by the manufacturer’s stability program and reviewed by FDA before marketing. A compounded preparation carries a beyond-use date established by the pharmacy that made it. Pharmacy literature treats the establishment and maintenance of that date as an ongoing professional obligation tied to the specific formulation, container and preparation category, not as a number copied across products.

Because compounded drugs are not FDA-approved and the agency does not review them for safety, effectiveness or quality before marketing, there is no central record a patient or prescriber can look up. Monitoring in this setting therefore means keeping the paper trail intact rather than consulting a public database.

Who is supposed to be watching what

Three parties usually touch a compounded prescription: the prescriber, the compounding pharmacy, and often a telehealth platform sitting between them. Each has a piece of the record and none has all of it. The prescriber holds clinical history and the treatment plan. The pharmacy holds the formulation, the lot, the testing and the dating rationale. The platform holds billing and shipping.

Analysis aimed at clinicians handling compounded semaglutide has made the point that prescribers frequently do not know the formulation details of what their patient received, and the same gap applies to tirzepatide. FDA has separately observed that consumers buying compounded drugs online may not know the identity of the compounder at all. When nobody can name the pharmacy, nobody can confirm the date either.

Closing that gap starts with knowing who is willing to name the pharmacy in the first place. Telehealth services vary widely here. Henry Meds and Hims & Hers describe their supply arrangements at a high level, LillyDirect connects eligible patients to the approved medicine, and a telehealth service such as HealthRX publishes a dedicated page on compounded tirzepatide covering how the product is stored and dated. Checking that kind of disclosure before enrolling makes the later follow-up far less fragile.

Follow-up item	Who actually holds it	Where it slips
The beyond-use date for this batch	The compounding pharmacy	Never transcribed into the patient’s own record
Lot number and carton	Patient, once shipped	Packaging discarded, making later tracing impossible
Formulation and concentration	Pharmacy, sometimes not shared onward	Prescriber assumes a strength that was never dispensed
Refill timing against the date	Platform scheduling	Shipment cadence and dating drift apart
Tolerability and clinical response	Prescriber	Asynchronous check-ins skipped once things feel stable
Adverse event reporting	Nobody by default	No federal reporting duty for most compounding pharmacies

The reporting gap is structural, not incidental

Federal compounding law separates state-licensed pharmacies operating under section 503A from outsourcing facilities registered under section 503B, a split created by the Drug Quality and Security Act in 2013. Outsourcing facilities are inspected by FDA on a risk-based schedule, follow current good manufacturing practice, and must report adverse events. Pharmacies compounding under 503A are overseen primarily by state boards and carry no equivalent federal reporting duty.

That difference shapes what anyone can learn after the fact. FDA has said adverse events from compounded versions of these drugs are likely underreported for exactly this reason. Pharmacy compounding literature reviewing patient adverse events with compounded GLP-1 products describes the same visibility problem. Follow-up that relies on national signal detection to catch a problem is relying on a system that was never built to catch it.

What a useful check-in actually covers

Good follow-up for compounded therapy is not only about tolerability and response, though those matter. It also verifies supply chain facts that quietly change: whether the pharmacy is the same one as last time, whether the concentration on the label matches the previous fill, and whether the date on the incoming vial leaves room before the next shipment. Laboratory work comparing follow-on GLP-1 polypeptide preparations has shown that manufacturing and compounding processes affect the properties and quality of the finished product, which is why a change in source is a clinical fact rather than an administrative one.

Refill timing is where this becomes concrete. The two parties who can reconcile a shipping schedule against a printed date are the compounding pharmacy named on the carton and the provider behind it. Services differ in how easily either can be reached once an order has shipped, and Ro, Found Health and Sesame publish different amounts of detail about their pharmacy relationships, so it is worth establishing before the first refill rather than during a gap.

Keep the packaging until the vial is finished

The single cheapest monitoring habit is holding on to the carton and label until the preparation is done. The lot number is what connects an individual vial to a batch record, a recall notice, or an adverse event report. FDA has noted that labels on compounded drugs may not carry all the information needed for safe use, which makes the fragments that are printed more valuable rather than less. A photograph of the label at delivery costs nothing and preserves the date, the lot and the pharmacy name even if the box is thrown out.

When treatment pauses or stops

Follow-up planning should also cover interruptions, because supply gaps and discontinuation are common in this drug class and have their own consequences for weight and metabolic measures. A pause caused by a lapsed date is different from a planned stop, and the response is a conversation with the prescriber about restarting rather than a decision made alone at the refrigerator door.

Frequently asked questions

Should the beyond-use date be recorded somewhere other than the vial?

Ideally yes. Writing the date, lot number and pharmacy name into a phone note at delivery means the information survives the packaging. It also makes the next check-in more useful, because the prescriber can compare what was dispensed this time against what was dispensed before.

How often should the pharmacy identity be confirmed?

At every fill. Compounding sources can change without any visible difference to the patient, and process differences affect finished product quality. If the name on the label is new, that is worth raising with the prescriber before the first dose from the new supply.

Does an outsourcing facility offer more oversight than a local pharmacy?

It operates under a different federal regime. Outsourcing facilities registered under section 503B follow current good manufacturing practice, are inspected by FDA on a risk-based schedule, and report adverse events. Neither route makes a compounded drug FDA-approved, but the oversight and reporting obligations are not equivalent.

What happens if a shipment arrives after the previous vial has dated out?

That is a scheduling problem to raise with the pharmacy and prescriber, not a problem to solve by extending use of the old vial. FDA states plainly that poor quality compounded preparations can cause serious injury, and a lapsed date is precisely the situation the date exists to prevent.

Where do adverse events go if the pharmacy is not required to report them?

Patients and clinicians can report directly to FDA through MedWatch. Because most compounding pharmacies outside the outsourcing facility category have no federal reporting duty, voluntary reports carry more weight in this category than they do for approved products.